Treat the disease plus reduce pain and inflammation


Starting treatment early with Adequan® Canine (polysulfated glycosaminoglycan) when you first identify arthritis in your canine patients can help slow the progression of cartilage deterioration in the dog’s synovial joints.

Adequan Canine reaches synovial joints within two hours and lasts for approximately three days.1 Once in the joint, Adequan Canine begins helping to restore joint tissues that are damaged or inflamed. The specific mechanism of action of Adequan® in canine joints is not known.

Treatment and retreatment with Adequan Canine

Recommended
dose

Recommended dose of Adequan Canine is 2 mg/lb body weight (0.02 mL/lb or 1 mL/50 lbs) by intramuscular injection only.1

Administration
schedule

Administer twice weekly for up to 4 weeks (maximum of 8 injections) at the approved dosage. Do not exceed the recommended dose or therapeutic regimen.

Pet parents may see signs of improvement in their dog’s mobility within one month.2

Monitoring
and follow-up

After the initial series, work with clients to monitor their dog’s joint health and mobility. The dosing regimen can be repeated as needed over the dog’s lifetime upon reoccurrence of clinical signs.

Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

INDICATIONS AND USAGE
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information.

Why is treating proactively important?

SHOW TRANSCRIPT

Get resources to support your recommendation


Check out our library of resources for handy tools to facilitate your conversations with clients about their dog’s joint health.

ACCESS RESOURCE LIBRARY

Let’s keep in touch

Stay in the know about the latest Adequan® Canine news, information, resources and more.

GET UPDATES

  1. Adequan® Canine (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
  2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1997.